Introduction
In a previous paper we reported on the determination of cefotaxime and desacetyl cefotaxime in human and rat serum after an i.v. injection of this cephalosporin (1) ; the concentrations of the parent compound and its metabolite in human bile were also briefly described. It has been shown that older cephalosporins with a 3~ acetoxymethyl substituent, e. g. cephalothin, are metabolised to the respective desacetyl compounds (2) . The degradation of cefotaxime to desacetyl cefotaxime has also been observed in man and was simultaneously reported from other laboratories (3, 4) . The purpose of this paper is to report in detail on the concentrations of cefotaxime and its antimicrobially active metabolite in human bile, measured both by high performance liquid chromatography (HPLC) and by bioassay with a selective test organism after an i.v. injection of 2 g.
Patients and Methods
Ten patients, three men and seven women aged between 32 and 82 years, were given a loading dose of 2 g cefotaxime administered i.v. over 3 min. The patients were selected for the study if physical examination suggested an infection of the gall bladder. None of the patients had received any antibacterial drugs beforehand. Informed written consent was obtained from each patient. Bile was collected through a catheter inserted into the bile duct as for ERCP and collected in nine fractions: before the injection of cefotaxime and 5, 10, 30, 60, 90, 120, 240 and 360 min after Pseudomonas aeruginosa K 1118 and E. coli V 6311/65 (1, (7) (8) (9) . On the other hand, high antibiotic concentrations in serum seem to be more important than bile levels of antibiotics in reducing the risk of infectious complications following gall bladder extirpation (10, 11) . Cephalosporins usually achieve high concentrations in the bile (12) (13) (14) (15) (16) and are generally highly effective against those organisms most commonly isolated from the biliary tract (17) . Therefore, preoperative administration of cephalosporins such as cefotaxime should reduce the risk of infectious complications during complicated cholecystectomy when anti-infective prophylaxis is indicated (18) .
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